TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03945721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a type of drug called a PARP inhibitor, which blocks DNA (the genetic material of cells) damage from being repaired or may prevent damage from occurring in the first place. In cancer treatment, inhibiting PARP may help kill cancer cells by not allowing the cancer cells to repair its DNA damage or prevent DNA damage from occurring.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: radiation therapy
Study: NCT01635101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: IV Acetaminophen given every 6 hours (q6h); 4 doses, in 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Control
Description: IV Control q6h; 4 doses, in 24 hours
Study: NCT02034279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Intravenous infusion of 20% albumin
Study: NCT02043249

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: CORD MILKING
Description: MILKING OF UMBILICAL CORD OF THE BABY
Study: NCT02569723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbon C 14 Oxaliplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenous infusion
Study: NCT02814851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiogram
Description: All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann. A transesophageal echocardiogram (TEE) will be performed and the TEE probe will stay continuously during the entire procedure, to allow all necessary measurements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermistor-tipped catheter
Description: All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a thermistor-tipped catheter (model 93A-131-7F, Edwards, Santa Ana, CA) will be inserted into the pulmonary artery to measure right atrial pressure (Pra), pulmonary arterial pressure (Ppa), Ppao and thermodilution cardiac output. Ringer's lactate will be infused to maintain an occluded pulmonary arterial pressure (Ppao) of 8-10 mmHg.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pressure/volume catheter
Description: All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a pressure/volume catheter (CD Leicom, Zoetermeer, Netherland) will be placed in the left ventricle through a left superior pulmonary vein purse string, in order to measure alternatively LV pressure/volume loops and LA pressure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: A complete transthoracic echocardiography will be performed the day before the surgical procedure. It will establish the presence of the inclusion and exclusion criteria, as stipulated above. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).~During the surgical procedure, a transesophageal echocardiogram will be performed, using an Acuson Sequoia system (Siemens AG, Germany).
Study: NCT02560584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hexaminolevulinate hydrochloride
Description: Instillation in bladder

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KARL STORZ D-Light C PDD Flexible Videoscope System
Description: Cystoscopy procedure
Study: NCT00940420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus (ribavirin)
Description: 800 - 1200 mg po daily for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus (ribavirin)
Description: 800 - 1200 mg po daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc once weekly for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc once weekly for 48 weeks
Study: NCT00709046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose pantoprazole infusion
Description: Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose pantoprazole infusion
Description: Pantoprazole 40mg iv bolus qd x 3 days
Study: NCT03618992

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cholesterol-containing moisturizers
Description: Commercially-available cholesterol containing topical formulations to be applied daily to the scalp, skin, lips, eyelashes, and eyebrows. Available from Skin Actives Scientific (www.skinactives.com).
Study: NCT03015012

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Personalized Nutrigenomics Testing (PNT)
Description: Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition and physical activity advice based on the results of their nutrigenomics test. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nutrition Intervention (SNI)
Description: Transplant participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition and physical activity counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the standard GLB Program. Transplant participants will receive a monthly follow-up email or phone call reviewing their nutrition and physical activity plan, until 12 months after baseline data collection. Reminders of lifestyle goals will be incorporated into the GLB Program for participants at the East Elgin Family Health Team.
Study: NCT02999945

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SGA-enhanced nutrients
Description: Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
Study: NCT05491070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular closure device (Angio-Seal, Progilde)
Description: In transfemoral TAVI, vascular closure devices were used for femoral artery wound closure, progilde and angio-seal can be used in wound closure. We aimed to compared the efficacy and safety of different vascular closure device in TAVI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular closure device (Angio-Seal, Progilde)
Description: In transfemoral TAVI, vascular closure devices were used for femoral artery wound closure, progilde and angio-seal can be used in wound closure. We aimed to compared the efficacy and safety of different vascular closure device in TAVI
Study: NCT02999945

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IUGR-enhanced nutrients
Description: Infants will receive fortified breast milk (\>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term

Intervention type: OTHER
Group type: OTHER
Intervention: SGA-standard nutrients
Description: Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)

Intervention type: OTHER
Group type: OTHER
Intervention: IUGR-standard nutrients
Description: Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
Study: NCT00402766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Starting Dose: 60 mg/m\^2 by vein, Over 2 Hours
Study: NCT01313845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amantadine sulfate
Description: infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
Study: NCT00402766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Starting Dose: 300 mg PO Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Starting Dose: 500 mg/m\^2 by vein, Over 40 Minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
Study: NCT03824912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole Cream 2%
Description: Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole Cream 2% (G&W Laboratories Inc.)
Description: Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 ± 4 days. Each patient is expected to receive 42 ± 4 doses.
Study: NCT04462003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: 10 mg/12 h for 1 week followed by 5 mg/12 h
Study: NCT01313845

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: infusion of normal saline 500ml/bottle over 3 hours twice a day
Study: NCT02979509

Intervention type: OTHER
Intervention: Endoscopic ultrasound- (EUS) guided tissue sampling
Description: EUS- guided tissue sampling of solid and/or cystic pancreatic and non-pancreatic lesions as part of their medical care.
Study: NCT03294239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral extraction of bladder stone(s)
Description: Patients will have transurethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone distentegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous extraction of bladder stone(s)
Description: Patients will have percutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the midline 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
Study: NCT00645528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Education Class
Description: Participation in an Insulin Education Class at week 0 and week 2
Study: NCT02239835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV) low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir (TPV) high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir high dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saquinavir
Study: NCT03718572

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Description: Surgical removal of Gall bladder using laparoscopy

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Description: Surgical removal of Gall bladder using laparoscopy
Study: NCT01327053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Description: LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
Study: NCT04017923

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of nasal tip support in different age groups.
Description: Nasal tip resistances , were measured in all age groups with a digital Newton meter.

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of nasal tip support in different age groups.
Description: Nasal tip resistances , were measured in all age groups with a digital Newton meter.

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of nasal tip support in different age groups.
Description: Nasal tip resistances , were measured in all age groups with a digital Newton meter.

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of nasal tip support in different age groups.
Description: Nasal tip resistances , were measured in all age groups with a digital Newton meter.
Study: NCT03232645

Intervention type: DEVICE
Group type: OTHER
Intervention: Ablation procedure
Description: Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
Study: NCT00551915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AR51 (12, 10)
Description: vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR51 (3, 10)
Description: vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
Study: NCT01627314

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Untreated CB
Description: Cord Blood
Study: NCT00156507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma education for parents of very low birth weight infants
Description: Asthma education is provided to parents of children in the experimental group prior to nicu discharge.
Study: NCT00862030

Intervention type: PROCEDURE
Intervention: CT- simulation scan
Description: Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
Study: NCT00982072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: tacrolimus0.05mg/kg bd (levels 6-12ng/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: Prednisolone 1mg/kg maximum 60mg od
Study: NCT02085772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples at 37-38 Weeks of amenorrhea
Study: NCT00551915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR51 (6, 10)
Description: vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PENTACEL™
Description: licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RECOMBIVAX HB™
Description: licensed vaccine for hepatitis, administered open-label
Study: NCT05166278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: De-escalation training
Description: The intervention will include training on verbal and nonverbal de-escalation techniques. The training will be prepared according to the recommendations of the Beta Project of the American Association for Emergency Psychiatry, the World Health Organization Quality Rights training to act, unite and empower for mental health and a handbook for the use of de-escalation skills in a hospital setting by Amdur E. The first part of the education is based on theoretical backgrounds: aggressive behavior in a psychiatric patient, risk factors, focusing on factors that can be modified, communication, de-escalation. The second part is a practical workshop. The training will be 16 hour duration in total. A short handbook and a list of verbal and non-verbal approaches will be prepared for all staff members involved in the training.
Study: NCT00096148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02085772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples at 41 Weeks of amenorrhea if prolonged pregnancy
Study: NCT00096148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02136680

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CASA Education
Description: Basic palliative care competencies for outpatient use.
Study: NCT04462003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: 1mg/Kg/sc/12h
Study: NCT02322567

Intervention type: OTHER
Intervention: medical records
Description: review of medical records

Intervention type: OTHER
Intervention: medical records
Description: review of medical records
Study: NCT03408756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Participants will receive methotrexate through oral or subcutaneous route of administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Participants will receive methotrexate through oral or subcutaneous route of administration
Study: NCT02111772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rhinovirus

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rhinovirus
Study: NCT01549093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine,Carboplatin,Endostar
Description: Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2\*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine(G) Carboplatin(C) Endostar
Description: Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine(G) Carboplatin(C)
Description: Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles
Study: NCT01705184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
Study: NCT01059825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Ertugliflozin
Description: Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
Study: NCT02085772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples at the time of delivery
Study: NCT00745875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: 10mg oral tablet, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500mg2/m IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: 500mg2/m IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg oral tablet, once daily